Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.37 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6911054 | 0.99 | GLA (0.51) | GLAHTTPOLBHSP90AA1KMT2A | |
| Bromide SCHEMBL1194102 | 0.86 | KAT6A (0.54) | GLAHTTKMT2AALDH1A1MEN1 | |
| Bromide SCHEMBL1194435 | 0.85 | GAA (0.52) | GLAPOLBHSP90AA1KMT2AALDH1A1 | |
| Bromide SCHEMBL1194675 | 0.85 | GLA (0.51) | GLAHTTPOLBHSP90AA1KMT2A | |
| SCHEMBL6224184 | 0.84 | GAA (0.53) | GLAPOLBHSP90AA1KMT2AALDH1A1 | |
| SCHEMBL6229503 | 0.84 | GLA (0.49) | GLAHTTPOLBHSP90AA1KMT2A | |
| Bromide SCHEMBL7695782 | 0.83 | GLA (0.48) | GLAHTTPOLBHSP90AA1KMT2A | |
| Bromide SCHEMBL7113514 | 0.83 | GLA (0.48) | GLAHTTPOLBHSP90AA1KMT2A | |
| Bromide SCHEMBL6225758 | 0.82 | GLA (0.55) | GLAHTTPOLBHSP90AA1KMT2A | |
| Bromide SCHEMBL1194019 | 0.81 | GLA (0.60) | GLAHTTHSP90AA1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2659933-A1 | Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc. | Torrent Pharmaceuticals Ltd. (IN) | 2013-11-06 | — | — | EP | claimed |
| JP-2011510067-A | — | — | 2011-03-31 | — | — | JP | claimed |
| US-20110034378-A1 | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. | TORRENT PHARMACEUTICALS LTD. (IN) | 2011-02-10 | — | — | US | claimed |
| EP-2254563-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING SPECIFIED AGE BREAKER AND FURTHER DRUGS, I.A. ANTIHYPERTENSIVE DRUGS, ANTIDIABETIC DRUGS ETC | Torrent Pharmaceuticals Ltd. (IN) | 2010-12-01 | — | — | EP | claimed |
| WO-2009093264-A2 | PHARMACEUTICAL COMBINATIONS | TORRENT PHARMACEUTICALS LTD. (IN) | 2009-07-30 | — | — | WO | claimed |
| EP-1222171-B1 | PYRIDINIUM DERIVATIVES FOR THE MANAGEMENT OF AGING-RELATED AND DIABETIC VASCULAR COMPLICATIONS, PROCESS FOR THEIR PREPARATION AND THERAPEUTIC USES THEREOF | TORRENT PHARMACEUTICALS LTD (IN) | 2004-02-25 | — | — | EP | claimed |
| US-20030092744-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. | 2003-05-15 | — | — | US | claimed |
| EP-1304101-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | Torrent Pharmaceuticals Ltd (IN) | 2003-04-23 | — | — | EP | claimed |
| US-20030032660-A1 | Breaking preformed AGE | TORRENT PHARMACEUTICALS LTD. | 2003-02-13 | — | — | US | claimed |
| US-6462057-B1 | SUCH AS 1-(2-ETHOXY-2-OXOETHYL)-3-(METHANESULFONYLHYDRAZINO-CARBONYL)PYRIDINIUM BROMIDE; KIDNEY DISEASE, NERVE DAMAGE, ATHEROSCLEROSIS, RETINOPATHY, DERMATOLOGICAL DISORDERS AND DISCOLORATION OF TEETH | TORRENT PHARMACEUTICALS, LTD. (IN) | 2002-10-08 | — | — | US | claimed |
| US-20020103228-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | TORRENT PHARMACEUTICALS LTD. | 2002-08-01 | — | — | US | claimed |
| US-20010018524-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2001-08-30 | — | — | US | claimed |
| EP-2659933-A1 | Pharmaceutical combinations comprising specified age breaker and further drugs, i.a. antihypertensive drugs, antidiabetic drugs etc. | Torrent Pharmaceuticals Ltd. (IN) | 2013-11-06 | — | — | EP | disclosed |
| US-20110034378-A1 | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. | TORRENT PHARMACEUTICALS LTD. (IN) | 2011-02-10 | — | — | US | disclosed |
| EP-2254563-A2 | PHARMACEUTICAL COMBINATIONS COMPRISING SPECIFIED AGE BREAKER AND FURTHER DRUGS, I.A. ANTIHYPERTENSIVE DRUGS, ANTIDIABETIC DRUGS ETC | Torrent Pharmaceuticals Ltd. (IN) | 2010-12-01 | — | — | EP | disclosed |
| WO-2009093264-A2 | PHARMACEUTICAL COMBINATIONS | TORRENT PHARMACEUTICALS LTD. (IN) | 2009-07-30 | — | — | WO | disclosed |
| US-20030032660-A1 | Breaking preformed AGE | TORRENT PHARMACEUTICALS LTD. | 2003-02-13 | — | — | US | disclosed |
| US-6462057-B1 | SUCH AS 1-(2-ETHOXY-2-OXOETHYL)-3-(METHANESULFONYLHYDRAZINO-CARBONYL)PYRIDINIUM BROMIDE; KIDNEY DISEASE, NERVE DAMAGE, ATHEROSCLEROSIS, RETINOPATHY, DERMATOLOGICAL DISORDERS AND DISCOLORATION OF TEETH | TORRENT PHARMACEUTICALS, LTD. (IN) | 2002-10-08 | — | — | US | disclosed |
| US-20020103228-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | TORRENT PHARMACEUTICALS LTD. | 2002-08-01 | — | — | US | disclosed |
| US-20010018524-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | TORRENT PHARMACEUTICALS LTD. (IN) | 2001-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018524-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | AGER, GLA, RBP1 | GLA 2/4885HTT 4615/4885POLB 632/4885 |
| US-20030092744-A1 | Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof | AGER, REN, RBP4 | GLA 5/4885HTT 4568/4885POLB 932/4885 |
| US-20030032660-A1 | Breaking preformed AGE | AGER, GPX1, RBP1 | GLA 22/4885HTT 4717/4885POLB 447/4885 |
| US-20020103228-A1 | Composition and method for use of pyridinium derivatives in cosmetic and therapeutic applications | PNPO, PRDX5, PLPBP | GLA 253/4885HTT 3647/4885POLB 715/4885 |
| US-20110034378-A1 | Pharmaceutical Combinations Comprising Specified Age Breaker and Further Drugs, I.A. Antihypertensive Drugs, Antidiabetic Drugs Etc. | AGER, F12, DPP4 | GLA 413/4885HTT 2640/4885POLB 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.